OncoMatch/Clinical Trials/NCT05722405
Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
Is NCT05722405 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies multiple treatments including Ixazomib plus low-dose lenalidomide and Ixazomib for multiple myeloma.
Treatment: Ixazomib plus low-dose lenalidomide · Ixazomib — Ixazomib combined with low-dose lenalidomide(10mg) vs Ixazomib alone as maintenance regimen in patients with high-risk multiple myeloma after induction and consolidation of VRD-based regimen.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Biomarker criteria
Required: CKS1B amplification
Required: FGFR3 fusion
Required: MAF fusion
Required: MAFB fusion
Required: TP53 deletion
Required: TP53 mutation
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Must have received: VRD regimen (bortezomib, lenalidomide, dexamethasone) induction and consolidation (bortezomib, lenalidomide, dexamethasone) — induction and consolidation
After induction and consolidation of the VRD regimen
Lab requirements
Kidney function
creatinine clearance (as estimated by cockcroft-gault) ≥ 60 ml/min (except for abnormal renal function due to multiple myeloma)
Liver function
serum alt and ast below 2.5 times the upper limit of normal; total bilirubin below 1.5 times the upper limit of normal
Cardiac function
cardiac ejection fraction ≥ 50%, no pericardial effusion confirmed by echocardiography, no clinically significant electrocardiographic findings
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify